According to a post on the FDA’s website, Juno Therapeutics’ lisocabtagene maraleucel received orphan designation. Juno Therapeutics is a Bristol-Myers Squibb company. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Bristol-Myers’ Juno get orphan designation for lisocabtagene maraleucel
- Bristol-Myers granted three applications for myeloma candidate Abecma
- MRK vs. BMY: Which Pharmaceutical Stock is Better?
- Bristol-Myers announces CHMP opinion recommending approval for Breyanzi
- Juno Therapeutics’ lisocabtagene maraleucel receives FDA orphan designation